Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
ABSTRACT Objective: To analyze the association of clinical, anatomical, and ultrasound (US) characteristics of malignancies in Bethesda III or IV (III-B or IV-B) thyroid nodules. Subjects and methods: The association between malignancies and the following variables were analyzed: III-B or IV-B, ag...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Brazilian Society of Endocrinology and Metabolism
2021-09-01
|
| Series: | Archives of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000500625&tlng=en |
| _version_ | 1819284443259469824 |
|---|---|
| author | Gustavo Cancela e Penna Camila Teixeira Costa Magda Carvalho Pires Tarcizo Afonso Nunes |
| author_facet | Gustavo Cancela e Penna Camila Teixeira Costa Magda Carvalho Pires Tarcizo Afonso Nunes |
| author_sort | Gustavo Cancela e Penna |
| collection | DOAJ |
| description | ABSTRACT Objective: To analyze the association of clinical, anatomical, and ultrasound (US) characteristics of malignancies in Bethesda III or IV (III-B or IV-B) thyroid nodules. Subjects and methods: The association between malignancies and the following variables were analyzed: III-B or IV-B, age < 55 years and ≥ 55 years, sex, family history of thyroid cancer, history of irradiation, nodule size, and ACR TI-RADS classification in 62 participants who underwent thyroidectomy. Results: Of the 62 participants, 87.1% (54/62) were women, 74.2% were < 55 years old, 95.2% had no family history of thyroid cancer, 56.5% had nodules < 2 cm in size, 62.9% were IV-B, and 69.4% were ACR TI-RADS 4. Thirty-two patients had thyroid carcinoma, and 30 had benign histology. Among all factors associated with malignancy, only ACR TI-RADS 5 classification on US was found to be statistically significant (p = 0.014), while III-B with architectural atypia cytological classification was the only one significantly associated with benign status (p = 0.004). Conclusion: Only a high risk of malignancy as assessed using US was able to refine the indication for molecular tests in a group of patients with indeterminate nodules. We found 85% (53/62) of III-B or IV-B thyroid nodules would benefit from available molecular diagnostic tests. |
| first_indexed | 2024-12-24T01:47:27Z |
| format | Article |
| id | doaj.art-2713ac30fddd47fda49906b65c9f6123 |
| institution | Directory Open Access Journal |
| issn | 2359-4292 |
| language | English |
| last_indexed | 2024-12-24T01:47:27Z |
| publishDate | 2021-09-01 |
| publisher | Brazilian Society of Endocrinology and Metabolism |
| record_format | Article |
| series | Archives of Endocrinology and Metabolism |
| spelling | doaj.art-2713ac30fddd47fda49906b65c9f61232022-12-21T17:21:50ZengBrazilian Society of Endocrinology and MetabolismArchives of Endocrinology and Metabolism2359-42922021-09-0165562563110.20945/2359-3997000000402Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?Gustavo Cancela e Pennahttps://orcid.org/0000-0003-2125-7051Camila Teixeira Costahttps://orcid.org/0000-0003-3227-1799Magda Carvalho Pireshttps://orcid.org/0000-0003-3312-4002Tarcizo Afonso Nuneshttps://orcid.org/0000-0001-7971-5786ABSTRACT Objective: To analyze the association of clinical, anatomical, and ultrasound (US) characteristics of malignancies in Bethesda III or IV (III-B or IV-B) thyroid nodules. Subjects and methods: The association between malignancies and the following variables were analyzed: III-B or IV-B, age < 55 years and ≥ 55 years, sex, family history of thyroid cancer, history of irradiation, nodule size, and ACR TI-RADS classification in 62 participants who underwent thyroidectomy. Results: Of the 62 participants, 87.1% (54/62) were women, 74.2% were < 55 years old, 95.2% had no family history of thyroid cancer, 56.5% had nodules < 2 cm in size, 62.9% were IV-B, and 69.4% were ACR TI-RADS 4. Thirty-two patients had thyroid carcinoma, and 30 had benign histology. Among all factors associated with malignancy, only ACR TI-RADS 5 classification on US was found to be statistically significant (p = 0.014), while III-B with architectural atypia cytological classification was the only one significantly associated with benign status (p = 0.004). Conclusion: Only a high risk of malignancy as assessed using US was able to refine the indication for molecular tests in a group of patients with indeterminate nodules. We found 85% (53/62) of III-B or IV-B thyroid nodules would benefit from available molecular diagnostic tests.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000500625&tlng=enThyroid nodulesindeterminate nodulesindeterminate thyroid nodulesmolecular testsmolecular diagnostic tests |
| spellingShingle | Gustavo Cancela e Penna Camila Teixeira Costa Magda Carvalho Pires Tarcizo Afonso Nunes Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? Archives of Endocrinology and Metabolism Thyroid nodules indeterminate nodules indeterminate thyroid nodules molecular tests molecular diagnostic tests |
| title | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
| title_full | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
| title_fullStr | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
| title_full_unstemmed | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
| title_short | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
| title_sort | are the anatomical clinical and ultrasound characteristics of thyroid nodules with bethesda iii or iv cytology and acr ti rads 3 4 or 5 able to refine the indications for molecular diagnostic tests |
| topic | Thyroid nodules indeterminate nodules indeterminate thyroid nodules molecular tests molecular diagnostic tests |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000500625&tlng=en |
| work_keys_str_mv | AT gustavocancelaepenna aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests AT camilateixeiracosta aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests AT magdacarvalhopires aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests AT tarcizoafonsonunes aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests |